Per our finalized policy in the CY 2025 OPPS/ASC final rule with comment period (89 FR 93932 through 93938), for new cell and gene therapy products that are not integral, ancillary, supportive, dependent, or adjunctive to any C-APC primary service, we will continue to add their product specific HCPCS codes, when created, to the C-APC exclusion list
Frost, PhD On November 6-7, the California Board of Pharmacy (BOP) is expected to vote to restrict access to safe and critical Category 1 substances like glutathione, NAD+ and methylcobalamin (the active and most bioavailable form of vitamin B12)
Frostegard, J
Ketogenic diet alleviates colitis by reduction of colonic group 3 innate lymphoid cells through altering gut microbiome
In mammals, the GPxs family consists of eight members (GPx1-GPx8) identified so far